-

Celltrion Group to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion Group today announced that the company will be attending the Morgan Stanley 21st Annual Global Healthcare Conference in New York City on Monday, September 11, 2023. Jungjin Seo, Chairman, will be speaking in a fireside chat at 3:35 p.m. ET.

Celltrion Group management will be participating in in-person meetings with investors on Monday, September 11, 2023. It will also be taking part in a New York IR roadshow on Tuesday, September 12 and Wednesday, September 13, 2023.

About Celltrion, Inc.

Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacture of biosimilar and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics.

For more information, visit www.celltrion.com

About Celltrion Healthcare

Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA Current Good Manufacturing Practice (cGMP) and the EU GMP guidelines. Celltrion Healthcare endeavors to offer high-quality, cost-effective solutions through an extensive global network that spans more than 110 different countries.

For more information, please visit: https://www.celltrionhealthcare.com/en-us/

Contacts

For further information please contact:
Lindsey Lucenta
llucenta@apcoworldwide.com
+1 260-444-1306

Industry:

Celltrion Healthcare

Release Versions
English

Contacts

For further information please contact:
Lindsey Lucenta
llucenta@apcoworldwide.com
+1 260-444-1306

More News From Celltrion Healthcare

Celltrion Receives EC Approval for Avtozma® (CT-P47), a Biosimilar to RoActemra® (tocilizumab)

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion today announced that the European Commission (EC) has granted marketing authorization for Avtozma® (CT-P47), a biosimilar referencing RoActemra® (tocilizumab). Avtozma® has been approved for all indications of its reference product, including moderate to severely active rheumatoid arthritis (RA), active systemic juvenile idiopathic arthritis (sJIA), polyarticular juvenile idiopathic arthritis (pJIA) and giant cell arteritis (GCA).1 The approval f...

Celltrion Unveils New Post-Hoc Analyses of LIBERTY Studies at the 20th ECCO Congress Further Evaluating the Efficacy and Safety of Subcutaneous (SC) Infliximab

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion announced new post-hoc analyses of its pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC), at the 20th European Crohn’s and Colitis Organisation (ECCO) Congress showcasing the treatment’s effectiveness across a range of key clinical outcomes in inflammatory bowel disease (IBD). The analyses highlight Celltrion’s ongoing efforts to evaluate the efficacy and safety of subcutaneous (SC) infliximab (CT-P13 SC) in achieving endoscopic-histologic remi...

Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt® (CT-P42, aflibercept), a biosimilar to Eylea® to treat multiple retinal disorders, including neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO, branch RVO or central RVO), diabetic macular edema (DME) and myopic choroidal neovascularisation (myopic C...
Back to Newsroom